FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992912488> ?p ?o ?g. }

• W1992912488 endingPage "139" @default.
• W1992912488 startingPage "136" @default.
• W1992912488 abstract "No AccessJournal of UrologyAdult urology1 Jan 2006Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer Matthew R. Smith, Simone Peart Boyce, Erick Moyneur, Mei Sheng Duh, Monika K. Raut, and Jane Brandman Matthew R. SmithMatthew R. Smith Hematology-Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals, Amgen and GTx. More articles by this author , Simone Peart BoyceSimone Peart Boyce Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author , Erick MoyneurErick Moyneur Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author , Mei Sheng DuhMei Sheng Duh Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author , Monika K. RautMonika K. Raut Novartis Pharmaceuticals Corp., East Hanover, New Jersey Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author , and Jane BrandmanJane Brandman Novartis Pharmaceuticals Corp., East Hanover, New Jersey Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00033-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the relationship between GnRH agonists and the risk of clinical fractures in men with prostate cancer. Materials and Methods: Using a database of medical claims from 16 large American companies we identified a study group of 3,779 men with prostate cancer who received treatment with a GnRH agonist and a control group of 8,341 with prostate cancer who were not treated with a GnRH agonist. Men with 1 or more medical claims for bone metastases were excluded. The rates of any clinical fracture, hip fracture and vertebral fracture were compared between the groups. Results: The rate of any fracture was 7.91/100 vs 6.55/100 person-years at risk in men who received vs did not receive a GnRH agonist (relative risk 1.21, 95% CI 1.09 to 1.34). The rates of hip fracture (relative risk 1.76, 95% CI 1.33 to 2.33) and vertebral fracture (relative risk 1.18, 95% CI 0.94 to 1.48) were also higher in men who received a GnRH agonist. GnRH agonist treatment was independently associated with fracture risk on multivariate analyses. Conclusions: GnRH agonists increase the risk of clinical fracture in men with prostate cancer. References 1 : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997; 337: 295. Crossref, Medline, Google Scholar 2 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar 3 : Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int1995; 57: 97. Google Scholar 4 : The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer1998; 83: 1561. Google Scholar 5 : Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999; 161: 1219. Link, Google Scholar 6 : Osteoporosis after orchiectomy for prostate cancer. J Urol1997; 157: 439. Link, Google Scholar 7 : Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer1997; 79: 545. Crossref, Medline, Google Scholar 8 : Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int2000; 86: 449. Google Scholar 9 : Skeletal fracture associated with androgen suppression induced osteoporosis the clinical incidence and risk factors for patients with prostate cancer. J Urol2001; 166: 1724. Abstract, Google Scholar 10 : Adapting a clinical comorbidity index for use with ICD-9-CM administrative data differing perspectives. J Clin Epidemiol1993; 46: 1075. Google Scholar 11 Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M. and Pashos, C. L.: Gonadotropin-releasing hormone (GnRH) agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer. Unpublished data. Google Scholar 12 : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154. Google Scholar 13 : Use of oral corticosteroids and risk of fractures. J Bone Miner Res2000; 15: 993. Google Scholar 14 : Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer2004; 100: 892. Google Scholar 15 : The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol2004; 172: 2137. Link, Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byKhriguian J, Tsui J, Vaughan R, Kucharczyk M, Nabid A, Bettahar R, Vincent L, Martin A, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M and Niazi T (2021) The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer PatientsJournal of Urology, VOL. 205, NO. 6, (1648-1654), Online publication date: 1-Jun-2021.Griebling T (2013) Re: Fracture after Androgen Deprivation Therapy among Men with a High Baseline Risk of Skeletal ComplicationsJournal of Urology, VOL. 191, NO. 2, (388-388), Online publication date: 1-Feb-2014.Morgans A, Hancock M, Barnette K, Steiner M, Morton R and Smith M (2012) Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 187, NO. 3, (889-893), Online publication date: 1-Mar-2012.Saylor P, Morton R, Hancock M, Barnette K, Steiner M and Smith M (2011) Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 186, NO. 2, (482-486), Online publication date: 1-Aug-2011.Alibhai S, Duong-Hua M, Cheung A, Sutradhar R, Warde P, Fleshner N and Paszat L (2010) Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 MenJournal of Urology, VOL. 184, NO. 3, (918-924), Online publication date: 1-Sep-2010.Saylor P, Kaufman D, Michaelson M, Lee R and Smith M (2010) Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 183, NO. 6, (2200-2205), Online publication date: 1-Jun-2010.Bhoopalam N, Campbell S, Moritz T, Broderick W, Iyer P, Arcenas A, Van Veldhuizen P, Friedman N, Reda D, Warren S and Garewal H (2009) Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation TherapyJournal of Urology, VOL. 182, NO. 5, (2257-2264), Online publication date: 1-Nov-2009.Israeli R, Ryan C and Jung L (2007) Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation TherapyJournal of Urology, VOL. 179, NO. 2, (414-423), Online publication date: 1-Feb-2008.Gilbert S, Dunn R and Wei J (2018) Re: Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate CancerJournal of Urology, VOL. 177, NO. 4, (1584-1585), Online publication date: 1-Apr-2007. Volume 175Issue 1January 2006Page: 136-139 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostateprostatic neoplasmsgonadorelinfracturesbone and bonesAcknowledgmentDrs. Jennifer Sung and Simu Thomas, Novartis Pharmaceuticals Corp. provided guidance and helpful comments.MetricsAuthor Information Matthew R. Smith Hematology-Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals, Amgen and GTx. More articles by this author Simone Peart Boyce Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author Erick Moyneur Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author Mei Sheng Duh Analysis Group, Inc., Boston, Massachusetts Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author Monika K. Raut Novartis Pharmaceuticals Corp., East Hanover, New Jersey Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author Jane Brandman Novartis Pharmaceuticals Corp., East Hanover, New Jersey Financial interest and/or other relationship with Novartis Pharmaceuticals. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1992912488 created "2016-06-24" @default.
• W1992912488 creator A5001111713 @default.
• W1992912488 creator A5004154463 @default.
• W1992912488 creator A5017925159 @default.
• W1992912488 creator A5049554190 @default.
• W1992912488 creator A5063896009 @default.
• W1992912488 creator A5075885313 @default.
• W1992912488 date "2006-01-01" @default.
• W1992912488 modified "2023-10-10" @default.
• W1992912488 title "Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer" @default.
• W1992912488 cites W1606563840 @default.
• W1992912488 cites W1997732940 @default.
• W1992912488 cites W2005383842 @default.
• W1992912488 cites W2011966376 @default.
• W1992912488 cites W2023227918 @default.
• W1992912488 cites W2026455376 @default.
• W1992912488 cites W2049096596 @default.
• W1992912488 cites W2080960491 @default.
• W1992912488 cites W2082333541 @default.
• W1992912488 cites W2083492047 @default.
• W1992912488 cites W2316095838 @default.
• W1992912488 cites W2337912524 @default.
• W1992912488 cites W4240322662 @default.
• W1992912488 cites W4255533032 @default.
• W1992912488 doi "https://doi.org/10.1016/s0022-5347(05)00033-9" @default.
• W1992912488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16406890" @default.
• W1992912488 hasPublicationYear "2006" @default.
• W1992912488 type Work @default.
• W1992912488 sameAs 1992912488 @default.
• W1992912488 citedByCount "179" @default.
• W1992912488 countsByYear W19929124882012 @default.
• W1992912488 countsByYear W19929124882013 @default.
• W1992912488 countsByYear W19929124882014 @default.
• W1992912488 countsByYear W19929124882015 @default.
• W1992912488 countsByYear W19929124882016 @default.
• W1992912488 countsByYear W19929124882017 @default.
• W1992912488 countsByYear W19929124882018 @default.
• W1992912488 countsByYear W19929124882019 @default.
• W1992912488 countsByYear W19929124882020 @default.
• W1992912488 countsByYear W19929124882021 @default.
• W1992912488 countsByYear W19929124882022 @default.
• W1992912488 countsByYear W19929124882023 @default.
• W1992912488 crossrefType "journal-article" @default.
• W1992912488 hasAuthorship W1992912488A5001111713 @default.
• W1992912488 hasAuthorship W1992912488A5004154463 @default.
• W1992912488 hasAuthorship W1992912488A5017925159 @default.
• W1992912488 hasAuthorship W1992912488A5049554190 @default.
• W1992912488 hasAuthorship W1992912488A5063896009 @default.
• W1992912488 hasAuthorship W1992912488A5075885313 @default.
• W1992912488 hasConcept C121608353 @default.
• W1992912488 hasConcept C126322002 @default.
• W1992912488 hasConcept C126894567 @default.
• W1992912488 hasConcept C143998085 @default.
• W1992912488 hasConcept C170493617 @default.
• W1992912488 hasConcept C2776235491 @default.
• W1992912488 hasConcept C2776363309 @default.
• W1992912488 hasConcept C2778575703 @default.
• W1992912488 hasConcept C2778894405 @default.
• W1992912488 hasConcept C2778938600 @default.
• W1992912488 hasConcept C2780192828 @default.
• W1992912488 hasConcept C2780275930 @default.
• W1992912488 hasConcept C29456083 @default.
• W1992912488 hasConcept C530470458 @default.
• W1992912488 hasConcept C71315377 @default.
• W1992912488 hasConcept C71924100 @default.
• W1992912488 hasConceptScore W1992912488C121608353 @default.
• W1992912488 hasConceptScore W1992912488C126322002 @default.
• W1992912488 hasConceptScore W1992912488C126894567 @default.
• W1992912488 hasConceptScore W1992912488C143998085 @default.
• W1992912488 hasConceptScore W1992912488C170493617 @default.
• W1992912488 hasConceptScore W1992912488C2776235491 @default.
• W1992912488 hasConceptScore W1992912488C2776363309 @default.
• W1992912488 hasConceptScore W1992912488C2778575703 @default.
• W1992912488 hasConceptScore W1992912488C2778894405 @default.
• W1992912488 hasConceptScore W1992912488C2778938600 @default.
• W1992912488 hasConceptScore W1992912488C2780192828 @default.
• W1992912488 hasConceptScore W1992912488C2780275930 @default.
• W1992912488 hasConceptScore W1992912488C29456083 @default.
• W1992912488 hasConceptScore W1992912488C530470458 @default.
• W1992912488 hasConceptScore W1992912488C71315377 @default.
• W1992912488 hasConceptScore W1992912488C71924100 @default.
• W1992912488 hasIssue "1" @default.
• W1992912488 hasLocation W19929124881 @default.
• W1992912488 hasLocation W19929124882 @default.
• W1992912488 hasOpenAccess W1992912488 @default.
• W1992912488 hasPrimaryLocation W19929124881 @default.
• W1992912488 hasRelatedWork W1750535794 @default.
• W1992912488 hasRelatedWork W1979621933 @default.
• W1992912488 hasRelatedWork W1985886098 @default.
• W1992912488 hasRelatedWork W2004268698 @default.
• W1992912488 hasRelatedWork W2050875469 @default.
• W1992912488 hasRelatedWork W2071423251 @default.
• W1992912488 hasRelatedWork W2403613161 @default.
• W1992912488 hasRelatedWork W2417748269 @default.
• W1992912488 hasRelatedWork W2583890993 @default.
• W1992912488 hasRelatedWork W4290773943 @default.
• W1992912488 hasVolume "175" @default.

• next